Skip to main content
Erschienen in:

24.11.2021 | Original Article

Possible relationship between IL28B rs12979860 and TLR2 -196 to -174 del/ins polymorphisms and the liver fibrosis stage in hepatitis C patients

verfasst von: Zehra Öksüz, Enver Üçbilek, Mehmet Sami Serin, Serkan Yaraş, Gülhan Örekici Temel, Orhan Sezgin

Erschienen in: Archives of Virology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

It has been shown that host factors play an important role in the progression of hepatitis C virus (HCV) infection. Toll-like receptor 2 (TLR2) del and interleukin 28B (IL28B) T alleles can mediate liver inflammation and pathogenesis of hepatocellular carcinoma. In the present study, the possible relationship between the IL28B rs12979860 C/T and TLR2 -196 to -174 del/ins gene variants and different fibrosis stages and host factors in hepatitis C patients was investigated. IL28B and TLR2 polymorphisms in the blood of 50 hepatitis C patients at different stages of fibrosis (24 mild/moderate, 26 advanced) and 24 healthy controls were examined by RT-qPCR. The highest frequency of the TLR2 del (26.9%) and IL28B T (46.2%) alleles was found in hepatitis C patients with the most advanced fibrosis, and the lowest frequency was found in healthy controls. There was a statistically significant difference between hepatitis C patients with advanced fibrosis and healthy controls in terms of the TLR2 del (p = 0.0062) and IL28B T (p = 0.0017) allele frequencies. However, no statistically significant difference was found between the mild/moderate fibrosis and severe fibrosis patient groups in terms of genotype or IL28B and TLR2 polymorphisms (p > 0.05). In addition, there was a significant difference between patients with mild/moderate or advanced fibrosis who carried the TLR2 del allele together with the IL28B CT genotype and healthy controls. The present study emphasizes that the TLR2 and IL28B gene variants cannot be single biomarkers for the determination of fibrosis stage in hepatitis C infection but together can play an important role in predicting severe disease.
Literatur
7.
Zurück zum Zitat De Re V, Tornesello ML, De Zorzi M, Caggiari L, Pezzuto F, Leone P, Racanelli V, Lauletta G, Gragnani L, Buonadonna A et al (2019) Clinical significance of polymorphisms in immune response genes in hepatitis C-related hepatocellular carcinoma. Front Microbiol 15(10):475. https://doi.org/10.3389/fmicb.2019.00475CrossRef De Re V, Tornesello ML, De Zorzi M, Caggiari L, Pezzuto F, Leone P, Racanelli V, Lauletta G, Gragnani L, Buonadonna A et al (2019) Clinical significance of polymorphisms in immune response genes in hepatitis C-related hepatocellular carcinoma. Front Microbiol 15(10):475. https://​doi.​org/​10.​3389/​fmicb.​2019.​00475CrossRef
9.
Zurück zum Zitat Tarantino G, Di Cristina A, Pipitone R, Almasio PL, Di Vita G, Craxi A, Grimaudo S (2013) In vivo liver expression of TLR2, TLR3 and TLR7 in chronic hepatitis C. J Biol Regul Homeost Agents 27:233–239PubMed Tarantino G, Di Cristina A, Pipitone R, Almasio PL, Di Vita G, Craxi A, Grimaudo S (2013) In vivo liver expression of TLR2, TLR3 and TLR7 in chronic hepatitis C. J Biol Regul Homeost Agents 27:233–239PubMed
10.
Zurück zum Zitat Nischalke HD, Coenen M, Berger C, Aldenhoff K, Müller T, Berg T et al (2012) The toll-like receptor 2 (TLR2) -196 to -174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C. Int J Cancer 6:1470–1475. https://doi.org/10.1002/ijc.26143CrossRef Nischalke HD, Coenen M, Berger C, Aldenhoff K, Müller T, Berg T et al (2012) The toll-like receptor 2 (TLR2) -196 to -174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C. Int J Cancer 6:1470–1475. https://​doi.​org/​10.​1002/​ijc.​26143CrossRef
12.
Zurück zum Zitat Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer R, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I, Chen S, Brand N, Tarway M et al (2013) A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 45:164–171. https://doi.org/10.1038/ng.2521CrossRefPubMedPubMedCentral Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer R, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I, Chen S, Brand N, Tarway M et al (2013) A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 45:164–171. https://​doi.​org/​10.​1038/​ng.​2521CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Mancuso ME, Linari S, Aghemo A, Bartolozzi D, Santagostino E, Rumi MG, Fognani E, Fasulo MR, Gragnani L, Bruno R, Morfini M, Zignego AL, Colombo M (2014) Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response. Thromb Haemost 111:1067–1076. https://doi.org/10.1160/TH13-11-897CrossRefPubMed Mancuso ME, Linari S, Aghemo A, Bartolozzi D, Santagostino E, Rumi MG, Fognani E, Fasulo MR, Gragnani L, Bruno R, Morfini M, Zignego AL, Colombo M (2014) Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response. Thromb Haemost 111:1067–1076. https://​doi.​org/​10.​1160/​TH13-11-897CrossRefPubMed
27.
Zurück zum Zitat De Re V, Gragnani L, Fognani E, Piluso A, Izzo F, Mangia A, Crovatto M, Gava G, Casarin P, Sansonno D, Racanelli V, De Vita S, Pioltelli P, Caggiari L, De Zorzi M, Berretta M, Gini A, Zucchetto A, Buonaguro FM, De Paoli P, Zignego AL (2014) Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection. Biomed Res Int. https://doi.org/10.1155/2014/710642CrossRefPubMedPubMedCentral De Re V, Gragnani L, Fognani E, Piluso A, Izzo F, Mangia A, Crovatto M, Gava G, Casarin P, Sansonno D, Racanelli V, De Vita S, Pioltelli P, Caggiari L, De Zorzi M, Berretta M, Gini A, Zucchetto A, Buonaguro FM, De Paoli P, Zignego AL (2014) Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection. Biomed Res Int. https://​doi.​org/​10.​1155/​2014/​710642CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Noureddin M, Wright EC, Alter HJ, Clark S, Thomas E, Chen R, Zhao X et al (2013) Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatol 58:1548–1557. https://doi.org/10.1002/hep.26506CrossRef Noureddin M, Wright EC, Alter HJ, Clark S, Thomas E, Chen R, Zhao X et al (2013) Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatol 58:1548–1557. https://​doi.​org/​10.​1002/​hep.​26506CrossRef
33.
Zurück zum Zitat Nosotti L, Petrelli A, Genovese D, Catone S, Argentini S, Vella S, Rossi A, Costanzo G, Fortino A, Chessa L, Miglioresi L, Mirisola C (2017) Distribution of IL28B polymorphism in a cohort of Italians and immigrants with HCV infection: association with viraemia, stage of fibrosis and response to treatment. J Immigr Minor Health 19:876–882. https://doi.org/10.1007/s10903-016-0444-9CrossRefPubMed Nosotti L, Petrelli A, Genovese D, Catone S, Argentini S, Vella S, Rossi A, Costanzo G, Fortino A, Chessa L, Miglioresi L, Mirisola C (2017) Distribution of IL28B polymorphism in a cohort of Italians and immigrants with HCV infection: association with viraemia, stage of fibrosis and response to treatment. J Immigr Minor Health 19:876–882. https://​doi.​org/​10.​1007/​s10903-016-0444-9CrossRefPubMed
Metadaten
Titel
Possible relationship between IL28B rs12979860 and TLR2 -196 to -174 del/ins polymorphisms and the liver fibrosis stage in hepatitis C patients
verfasst von
Zehra Öksüz
Enver Üçbilek
Mehmet Sami Serin
Serkan Yaraş
Gülhan Örekici Temel
Orhan Sezgin
Publikationsdatum
24.11.2021
Verlag
Springer Vienna
Erschienen in
Archives of Virology / Ausgabe 1/2022
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-021-05302-9

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Vorhofflimmern: Antikoagulation vor Schlaganfall von Vorteil

Erleiden Menschen mit Vorhofflimmern einen ischämischen Schlaganfall, ist dieser weniger schwer, auch sind Infarktgröße und Blutungsrisiko geringer, wenn sie zuvor orale Antikoagulanzien erhalten haben. Die Art der Antikoagulation spielt dabei keine Rolle.

Mehr Cholesterin im Essen = höheres Herzinfarktrisiko

Je mehr Cholesterin man täglich über die Nahrung zu sich nimmt, desto höher ist offenbar das Herzinfarktrisiko – das legt eine Studie mit US-Veteranen zumindest für Männer nahe.

Antikoagulation bei Vorhofflimmern: Sind DOAK noch zu toppen?

Gegen Thromboembolien so wirksam wie ein DOAK, bei zugleich geringerem Blutungsrisiko – werden Faktor-XI-Hemmer als neue Antikoagulanzien dieser Erwartung gerecht? Eine aktuell publizierte Vergleichsstudie gibt darüber Aufschluss.

"Stammzell-Pflaster" gegen geschwächte Herzen: Hoffnung oder Hype?

Eine Nature-Publikation zur Behandlung der Herzinsuffizienz mit von Stammzellen abgeleiteten Herzzellen sorgt in Publikumsmedien für Wirbel. Deren Erkenntnisse sind in der Tat spektakulär – und gleichzeitig vorläufig und ernüchternd. 

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.